Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CFTR | P13569 | 4/20 | 0.53 |
| ▸ | KCNH3 | Q9ULD8 | 4/20 | 0.47 |
| ▸ | RORC | P51449 | 2/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | VNN1 | O95497 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1554572 | 0.96 | MEN1 (0.51) | MEN1LMNAKMT2ATDP1L3MBTL1 | |
| SCHEMBL15905283 | 0.95 | PTK2 (0.51) | MEN1LMNAKMT2ATDP1L3MBTL1 | |
| SCHEMBL1554621 | 0.92 | MEN1 (0.47) | MEN1LMNAKMT2ATDP1L3MBTL1 | |
| SCHEMBL1555631 | 0.92 | L3MBTL1 (0.64) | MEN1LMNAKMT2ATDP1L3MBTL1 | |
| SCHEMBL2124834 | 0.90 | MEN1 (0.46) | MEN1LMNAKMT2ATDP1L3MBTL1 | |
| SCHEMBL2123078 | 0.89 | CFTR (0.45) | MEN1LMNAKMT2ATDP1L3MBTL1 | |
| SCHEMBL1555144 | 0.89 | FFAR1 (0.50) | MEN1LMNAKMT2ATDP1L3MBTL1 | |
| SCHEMBL1555624 | 0.89 | CFTR (0.45) | MEN1LMNAKMT2ATDP1L3MBTL1 | |
| SCHEMBL1554628 | 0.89 | MEN1 (0.53) | MEN1LMNAKMT2ATDP1L3MBTL1 | |
| SCHEMBL1555581 | 0.89 | CFTR (0.45) | MEN1LMNAKMT2ATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2697230-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2697230-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2697230-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2014-02-19 | — | — | EP | disclosed |
| US-8586584-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| US-8586584-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2488526-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2013-07-24 | — | — | EP | disclosed |
| US-8445490-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445490-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445490-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-21 | — | — | US | disclosed |
| WO-2012141704-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-18 | — | — | WO | disclosed |
| WO-2012141704-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-18 | — | — | WO | disclosed |
| EP-2488526-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120093766-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| US-20120093766-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| US-20120093766-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| WO-2011047119-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011047119-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | disclosed |
| US-20110086858-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-14 | — | — | US | disclosed |
| US-20110086858-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-14 | — | — | US | disclosed |
| US-20110086858-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093766-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, SLC10A1, HCCS | MEN1 4684/4885LMNA 3006/4885KMT2A 4752/4885 |
| US-20110086858-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, SLC10A1, HCCS | MEN1 4684/4885LMNA 3006/4885KMT2A 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.